Price movement over the last 24 hours
Global X Artificial Intelligence & Technology ETF vs McKesson Corporation — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.34, while McKesson Corporation trades at $817.75 (market cap $94.52B). The key difference: McKesson Corporation pays a 0.41% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| AIQ | MCK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $995.69 |
52-Week Low | $43.28 | $659.01 |
Market Cap | — | $94.52B |
Enterprise Value | — | $99.16B |
Dividend Yield | — | 0.41% |
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →